Phenotypic and transcriptomic characterisation of a novel biallelic RNU2-2 developmental and epileptic encephalopathy

This study identifies 14 individuals with severe developmental and epileptic encephalopathy caused by rare biallelic *RNU2-2* variants, characterizing a distinct clinical phenotype and demonstrating that aberrant splicing events are detectable via RNA sequencing in fibroblast but not blood tissues.

The Gist

The Big Picture: A Broken Instruction Manual

Imagine your body is a massive, complex construction site. To build a human, you need a master instruction manual (your DNA) and a team of specialized workers (proteins) who read that manual and build the parts.

One specific team of workers is called the Spliceosome. Their job is to edit the raw instructions. Think of the raw instructions as a movie script that has too many scenes, some of which are nonsense. The Spliceosome's job is to cut out the "nonsense scenes" (introns) and stitch the good scenes (exons) together so the final movie (the protein) makes sense.

This paper is about a specific, tiny tool in that editing team called RNU2-2. It's like a specific pair of scissors or a specific highlighter pen that the editors use. The researchers discovered that if a child inherits two broken copies of this tool (one from mom, one from dad), the editing process goes haywire, leading to a severe condition called a Developmental and Epileptic Encephalopathy (DEE).

The Mystery: The "Unsolved" Cases

For years, doctors have used Whole Genome Sequencing (WGS) to look at a child's DNA to find the cause of severe epilepsy and developmental delays. However, about half the time, the test comes back saying, "We can't find the problem."

Why? Because standard tests are like looking for a missing brick in a wall. They look at the big, obvious genes. But this paper found that the problem was hiding in a tiny, non-coding part of the DNA (the RNU2-2 gene) that standard tests often ignore. It's like looking for a missing screw in a car engine, but the screw is so small and hidden that the mechanic's usual flashlight doesn't see it.

The Discovery: Finding the "Broken Scissors"

The researchers at the Karolinska Institute in Sweden went back to their files and looked specifically for these tiny, broken "scissors" (RNU2-2 variants).

• The Findings: They found 14 children from 9 families who all had two broken copies of this gene.
• The Pattern: These broken copies weren't scattered randomly; they were all clustered in the very first part of the tool (the 5' domain). It's like finding that every broken pair of scissors in a factory had a crack in the exact same spot on the handle.
• The Result: Because the tool is broken, the "editing" of the body's instructions fails. The body ends up with garbled, unusable proteins, which causes severe brain development issues.

The Symptoms: A Severe "Glitch"

The children with this condition share a very specific, severe set of symptoms. You can think of their brains as a computer that is constantly crashing and rebooting.

• Seizures: They have severe, drug-resistant seizures. The most common types are "tonic" (stiffening) and "spasms." It's like the brain's electrical system is short-circuiting constantly.
• Development: They have profound intellectual disabilities. Most cannot walk, talk, or even sit up on their own. It's as if the construction site never got past the foundation stage.
• Movement: Many have involuntary movements (dancing, jerking) because the signals to the muscles are scrambled.
• The "Lennox-Gastaut" Syndrome: Many of these children fit into a specific, severe category of epilepsy known as Lennox-Gastaut syndrome.

The researchers used a "digital fingerprint" system (called HPO) to compare these 14 children against 700 other children with epilepsy. The 14 children with the broken RNU2-2 tool looked so similar to each other, and so different from the others, that the computer knew they were a distinct group.

The Proof: The "Fibroblast" Detective Work

Here is the clever part of the study. Usually, to check if a gene is broken, doctors take a blood sample. But when they checked the blood of these children, the broken tool didn't show up clearly. The "glitch" was invisible in the blood.

So, the researchers took a different approach. They took tiny skin cells (fibroblasts) from the children and grew them in a lab.

• The Analogy: Imagine blood is like a quiet library where the noise of the broken scissors is drowned out. But skin cells are like a busy construction site where the broken scissors are actually being used.
• The Result: When they looked at the skin cells, they saw the "garbage" instructions piling up. The editing process was clearly failing. This proved that the broken RNU2-2 gene was indeed the cause of the disease.

Why This Matters

1. Solving the Unsolved: This gives a name and a cause to a group of children who previously had no answers. It means doctors can stop looking for other causes and focus on managing this specific condition.
2. A New Test: The study suggests that for future cases, if a standard blood test is negative but the symptoms match, doctors should try testing skin cells (fibroblasts) using RNA sequencing. It's like realizing you need a different kind of flashlight to find the missing screw.
3. Frequency: Surprisingly, this "rare" disease is actually found in about 0.65% of children with severe epilepsy at their hospital. That means it's more common than previously thought, and many more families might be affected.

In Summary

This paper is a detective story where scientists found a tiny, broken tool (RNU2-2) that was causing a massive construction failure in the brains of 14 children. By changing how they looked for the evidence (switching from blood to skin cells), they proved that this broken tool causes a severe form of epilepsy and developmental delay. This discovery offers hope for diagnosis and a roadmap for finding similar cases in the future.

Technical Summary

1. Problem Statement

• Diagnostic Gap: Approximately 50% of individuals with suspected genetic Developmental and Epileptic Encephalopathies (DEEs) remain undiagnosed even after Whole Genome Sequencing (WGS).
• Non-coding Variant Challenge: Standard clinical pipelines often fail to prioritize or classify pathogenic variants in non-coding regions, such as small nuclear RNA (snRNA) genes.
• Specific Knowledge Gap: While dominant variants in RNU2-2 (encoding U2 snRNA) were recently linked to neurodevelopmental disorders, the existence and clinical significance of biallelic (recessive) RNU2-2 variants were not well characterized. Previous large-scale population databases were required to identify dominant variants, a method not feasible for rare recessive conditions in clinical settings.
• Validation Need: There is a lack of established functional assays (e.g., RNA sequencing) to validate the pathogenicity of rare, non-recurrent recessive variants in snRNA genes.

2. Methodology

The study employed a multi-modal approach combining deep phenotyping, genomic screening, and transcriptomic analysis:

• Cohort Screening:
  • Screened 28,196 individuals/families from the Genomic Medicine Centre Karolinska for Rare Diseases (GMCK-RD) for biallelic RNU2-2 variants.
  • Filtering Criteria: Variants were prioritized based on zygosity (biallelic), ultra-rare frequency (MAF ≤ 0.0000723 in gnomAD v4.1.0 non-UKB), location (within the snRNA-encoding region), and phenotypic concordance.
  • Exclusion: Variants found in homozygous states in large control databases or lacking variants in the conserved 5' domain were excluded.
• Deep Phenotyping:
  • Medical records of 14 identified individuals were reviewed.
  • Phenotypic traits were converted to Human Phenotype Ontology (HPO) terms.
  • Statistical Analysis: Pairwise phenotypic similarity scores were calculated using the OntologySimilarity package in R. A two-sided Monte Carlo permutation test compared the RNU2-2 cohort ($n=9$, siblings excluded) against a broader epilepsy cohort ($n=703$) to assess phenotypic enrichment.
• Genomic Confirmation:
  • Sanger sequencing was used to confirm variants, verify trans configuration in parents, and check segregation in unaffected siblings.
• Transcriptomic Analysis (RNA-seq):
  • Samples: RNA was extracted from blood and cultured fibroblasts from RNU2-2 patients, a validation cohort with RNU4-2 variants, and independent controls.
  • Pipeline: Used the Tomte pipeline and DROP (Detection of RNA Outliers Pipeline) for outlier analysis.
  • Splicing Analysis: rMATS-turbo was used for differential splicing analysis (filtering for FDR < 0.1 and $\Delta$PSI > 0.05). Principal Component Analysis (PCA) was performed on Percent Spliced In (PSI) values.
  • Expression Analysis: DESeq2 was used for differential gene expression analysis.

3. Key Contributions

• Novel Disease Entity: Defined a distinct, severe recessive disorder caused by biallelic RNU2-2 variants, characterized by a highly concordant DEE phenotype.
• Variant Characterization: Identified 12 ultra-rare biallelic variants across 14 individuals, noting a strong clustering in the conserved 5' domains (specifically Stem Loop I, the Branch Point Recognition Sequence, and Stem Loop II).
• Tissue-Specific Validation: Demonstrated that fibroblast RNA sequencing is a superior method for detecting aberrant splicing in RNU2-2 disorders compared to blood, providing a novel clinical validation workflow for non-coding variants.
• Phenotypic Homogeneity: Quantified the phenotypic similarity of this cohort, proving it is a distinct entity within the broader spectrum of pediatric epilepsies.

4. Key Results

A. Genomic Findings

• Prevalence: The biallelic RNU2-2 disorder was found in 0.65% of families with suspected genetic epilepsies at the CMMS center, suggesting it is a relatively common "rare" disease.
• Variant Distribution: 10/12 variants were compound heterozygous; 3 individuals had homozygous variants. All pathogenic variants (except one) occurred in the conserved 5' region (n.61 or earlier).
• Recurrence: Most variants were recurrent within the cohort or matched recently published preprints, confirming a specific mutational hotspot.

B. Clinical Phenotype (Deep Phenotyping)

• Core Features: All 14 individuals presented with severe to profound intellectual disability, inability to walk or communicate, and refractory seizures.
• Seizure Profile:
  • Onset: Median age 10.5 months (early onset).
  • Types: Tonic seizures (100%), epileptic spasms (79%), and bilateral tonic-clonic seizures (62%).
  • Syndrome: 86% met criteria for Lennox-Gastaut Syndrome (LGS) or LGS-like phenotype; 71% progressed from Infantile Spasms Syndrome.
• Motor & Developmental:
  • Global developmental delay evident by 5.5 months.
  • 64% achieved unsupported sitting (delayed); only 1 individual walked independently (and later lost the skill).
  • 43% had no voluntary movement; 86% exhibited movement abnormalities (dystonia, choreoathetosis, hyperkinesia).
• Other Features: Brain MRI showed atrophy in 71%; recurrent infections, sleep disturbances, and tube feeding were common.

C. Transcriptomic Findings

• Splicing Aberrations:
  • Fibroblasts: Clear separation between RNU2-2 patients and controls was observed for mutually exclusive exon and alternate 3' splice site events.
  • Blood: No significant splicing differences were detected in blood samples, highlighting the tissue-specific nature of the defect.
• Validation: The splicing defects were validated using a second independent control group. The RNU4-2 positive control cohort showed similar tissue-specific patterns (stronger in fibroblasts), confirming the methodology.
• Expression: No significant differential gene expression was found, indicating the primary mechanism is splicing dysregulation rather than transcript abundance changes.

5. Significance

• Clinical Impact: This study identifies a new, treatable (in terms of diagnostic yield) cause of severe DEE. It suggests that patients with severe, early-onset DEE and negative WGS results should be screened for biallelic RNU2-2 variants.
• Methodological Advancement: The paper establishes fibroblast RNA sequencing as a critical tool for validating pathogenicity in non-coding snRNA genes where blood RNA-seq fails to show defects. This addresses a major bottleneck in diagnosing "unsolved" genetic cases.
• Pathophysiological Insight: The findings confirm that biallelic variants in the 5' conserved regions of RNU2-2 disrupt the major spliceosome, leading to widespread aberrant splicing (specifically in mutually exclusive exons and 3' splice sites) that drives a severe neurological phenotype.
• Differentiation: The study clearly delineates the recessive RNU2-2 disorder from the previously known dominant form, noting that the recessive form presents with earlier seizure onset, more severe motor impairment, and a higher prevalence of LGS-like phenotypes.